Ondansetron Hydrochloride Injection

This product is a potent and highly selective 5HT3 receptor antagonist with a strong antiemetic effect. Chemotherapy drugs and radiotherapy can cause the small intestine to release 5HT, which activates the afferent branch of the vagus nerve through the 5HT3 receptor and triggers the vomiting reflex. This product can block the triggering of this reflex. The stimulation of the afferent branch of the vagus nerve can also cause the release of 5HT in the Postrema area at the bottom of the fourth ventricle, thereby enhancing it through a central mechanism. This product has an antiemetic effect on nausea and vomiting caused by chemotherapy and radiotherapy by antagonizing the 5HT receptors of neurons located in the peripheral and central nervous systems. The mechanism of action of postoperative nausea and vomiting is unclear, but it may be induced by a common pathway similar to nausea and vomiting caused by cytotoxic drugs. This product can also inhibit nausea induced by opioids, and its mechanism of action is still unclear. Due to the high selectivity of this product, it does not have the side effects of other antiemetics, such as extrapyramidal reactions and excessive sedation.

Its chemical name is 1,2,3,9-tetrahydro-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-4-oxocarbazole hydrochloride. Molecular formula: C18H19N3O?HCl?2H2O Molecular weight: 365.83

This product is a colorless or almost colorless clear liquid.

Used for vomiting caused by radiotherapy and cytotoxic chemotherapy.

1 For vomiting caused by highly emetic chemotherapy drugs: 8 mg of ondansetron hydrochloride injection is injected intravenously 15 minutes before chemotherapy, 4 hours and 8 hours after chemotherapy, and 8 mg of ondansetron hydrochloride tablets are taken orally every 8 hours after chemotherapy is stopped, and it is used for 5 consecutive days. 2 For vomiting caused by chemotherapy drugs that are not so emetic: 8 mg of ondansetron hydrochloride injection is injected intravenously 15 minutes before chemotherapy, and 8 mg of ondansetron hydrochloride tablets are taken orally every 8 hours thereafter, and it is used for 5 consecutive days. 3 For vomiting caused by radiotherapy: The first dose must be taken orally as a tablet 1-2 hours before radiotherapy, and 8 mg of ondansetron hydrochloride tablets are taken orally every 8 hours thereafter. The course of treatment depends on the course of radiotherapy.

There may be headache, abdominal discomfort, constipation, dry mouth, rash, occasional bronchial asthma or allergic reaction, transient asymptomatic increase in transaminase. The above reactions are mild and do not require special treatment. Movement disorders and epileptic seizures are occasionally seen. Chest pain, arrhythmia, hypotension and bradycardia are rare.

It is contraindicated for those who are allergic to this product. It is contraindicated for those who have gastrointestinal obstruction.

1. There is no evidence that this product will induce or inhibit the metabolism of other drugs taken at the same time. Special studies have shown that this product has no interaction with alcohol, temazepam, furosemide, tramadol and propofol. 2. Patients with poor metabolism of separteine and isoquine have no effect on the elimination half-life of this product. After repeated administration to such patients, the exposure level of the drug is no different from that of the normal human body, so the dosage and frequency of medication do not need to be changed. 3. Combination with dexamethasone can enhance the antiemetic effect. 4. It is compatible with the following intravenous injections: 0.9% W/V sodium chloride intravenous infusion solution (British Pharmacopoeia); 5% w/v glucose intravenous infusion solution (British Pharmacopoeia); 10% w/v mannose intravenous infusion solution (British Pharmacopoeia); Green's intravenous infusion solution; 0.3% W/V potassium chloride and 0.9% W/V glucose intravenous infusion solution (United States Pharmacopoeia); 0.3% w/V potassium chloride and 5% W/V glucose infusion solution (British Pharmacopoeia). This product can only be mixed with the recommended intravenous infusion solution, and the solution for intravenous infusion should be prepared immediately before use. However, under fluorescent irradiation at room temperature (below 25°C) or in a refrigerator, this product can remain stable for seven days after being mixed with the above intravenous infusion solution. 5 This product can be intravenously infused with an infusion bag or a syringe pump at 1 mg per hour. If the concentration of this product is 16-160mu;g/ml (i.e. 8mg/500ml and 8mg/50ml respectively), the following drugs can be administered through the Y-shaped tube of the ondansetron delivery device; cisplatin, 5Fu, carboplatin, etoposide, cyclophosphamide, doxorubicin and ceftriaxone, etc.

Store in a shaded, cool place. Validity period: three years.

2ml:4mg (based on ondansetron)

Liaoning Tianlong Pharmaceutical Co., Ltd.

• Founded in:

  1992-07-25

• Address:

  Panjin Economic Development Zone

• Tax NO.:

  91211103604381019Q

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view